Healthcare Industry News: DePuy AcroMed
News Release - June 21, 2006
St. Francis Medical Technologies Announces Appointment of Orthopedic Marketing Expert to Lead Sales and Marketing in Asia and South/Latin AmericaSAN FRANCISCO--(HSMN NewsFeed)--June 21, 2006--St. Francis Medical Technologies, Inc.® announced today that it has appointed Chester Huang, former director of sales and marketing for DePuy Spine, as leader of the company's Asia Pacific & South/Latin America strategic marketing and sales efforts. Mr. Huang brings to the company more than 12 years of experience building and leading orthopedic marketing and sales in the Asian Market.
Most recently, Mr. Huang was the director of sales and marketing for Asia Pacific, Canada and Latin America for DePuy Spine. In this role, he prepared annual business plans with revenue projections and operating budgets. He also managed sales budgets in excess of $100 million. Prior to taking up this position he spent nine years in various roles of increasing responsibility in marketing and sales management at DePuy AcroMed and DePuy Motech AcroMed, both Johnson & Johnson companies.
Preceding his time at DePuy, Mr. Huang worked in marketing, sales and business development for Schmidt Scientific Taiwan Ltd., where he led a team to import new medical products into the country. During his tenure at the company he negotiated and managed contracts represented by such companies as DePuy, AcroMed and Surgical Dynamics.
"Mr. Huang's ability to deliver outstanding results and build strong relationships with key clinicians will help expand St. Francis' international presence and help position the company as a global leader in the orthopedic industry," said Kevin Sidow, president and chief executive officer of St. Francis Medical Technologies.
About St. Francis Medical Technologies
St. Francis Medical Technologies is a privately held company based in Alameda, Calif., engaged in the discovery, development, manufacturing and marketing of novel treatments for degenerative spinal disorders worldwide. In November 2005, St. Francis received FDA approval for the X STOP, the first FDA-approved interspinous process implant to treat Lumbar Spinal Stenosis (LSS), a degenerative spinal disorder that may affect over two million Americans. As a result, patients and healthcare professionals finally have a safe and effective alternative to more aggressive, riskier procedures. For more information, please visit: www.sfmt.com.
Source: St. Francis Medical Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.